Posted inNews and Updates
ArkBio’s Ziresovir: Phase II FDA Trial Approval for RSV
ArkBio has secured FDA approval for a Phase II clinical trial of Ziresovir, a novel RSV antiviral drug. Learn how this treatment aims to combat the virus.
Posted inNews and Updates
ArkBio’s RSV Antiviral Ziresovir Enters Phase II Trials
ArkBio has received FDA clearance to launch Phase II clinical trials for Ziresovir, a novel RSV antiviral. Learn about this breakthrough treatment's potential.
Posted inNews and Updates
Aurobindo Pharma Receives FDA Warning Letter for Unit
Aurobindo Pharma faces an FDA warning letter at its Unit-XI facility due to cGMP violations. Discover the impact on drug manufacturing and compliance.
Posted inNews and Updates
Genomic Profiling in Pediatric Cancer: A Clinical Update
Discover how genomic profiling and precision medicine are transforming pediatric cancer treatment, improving diagnostic accuracy and clinical outcomes.
Posted inNews and Updates
AI in Healthcare: The Urgent Need for Clinical Evidence
AI-driven clinical decision support is surging, but is it safe? Explore the critical need for rigorous clinical evidence and oversight in medical AI.
Posted inNews and Updates
Atrium Therapeutics Launches PRKAG2 Syndrome Clinical Trial
Atrium Therapeutics has opened enrollment for a new PRKAG2 syndrome clinical trial in collaboration with BMS, targeting novel treatments for cardiac disease.
Posted inNews and Updates
Zipalertinib Shows Promise in Phase 3 EGFR Exon 20 Trial
Zipalertinib combined with chemotherapy hit its primary endpoint in a Phase 3 trial, offering new hope for patients with EGFR Exon 20 insertion mutations.
Posted inNews and Updates
FDA Grants Fast Track Status to Allogene’s TALEN Cell Therapy
The FDA has granted Fast Track status to Allogene’s TALEN-edited CAR-T therapy for lymphoma, promising a potential shift toward off-the-shelf treatments.
Posted inNews and Updates
Nektar Secures Funding for Rezpegaldesleukin Phase 3 Trials
Nektar Therapeutics secures funding to propel Phase 3 trials of rezpegaldesleukin through 2028, targeting advancements in autoimmune disease treatment.
Posted inNews and Updates
Ozekibart Progresses Toward FDA Review Despite Q2 Losses
Inhibrx reports Q2 2026 losses while advancing its lead candidate, ozekibart, toward a pivotal FDA review. Get the latest on this major oncology pipeline.